Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

Milestone Pharmaceuticals Inc. Common Shares

Thank you for your interest in Milestone Pharmaceuticals. While we encourage you to explore opportunities with our company, we urge you to be cautious and wary of recruitment scams in which fraudsters pose as representatives of Milestone Pharma. All current openings are available to view on our Careers page. https://milestonepharmaceuticals.applytojob.com/

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. Etripamil is a novel, potent and short-acting calcium channel blocker designed by Milestone and being developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of PSVT as they occur. Milestone is actively recruiting patients for a Phase 3 clinical trial of etripamil for the treatment of PSVT. Milestone plans to initiate a Phase 2 clinical trial in atrial fibrillation, another rapid heart rate condition, and expects to subsequently initiate an additional Phase 2 clinical trial in angina to establish proof-of-concept for the broader use of etripamil.

RTW Investments

Amplitude Venture Capital

Tekla Capital Management

BDC Capital Corporation

Boxer Capital

Novo Holdings

GO CAPITAL

Pappas Capital

Domain Associates

Fonds de solidarité FTQ

Forbion Capital Partners

Milestone Pharmaceuticals, Inc.

Today, there is a critical need for an innovative, novel treatment solution to support patients experiencing debilitating heart conditions.
 
Recently, we had the opportunity to join the #cardiovascular community in Washington D.C. to discuss the latest clinical trials to advance treatments for these conditions at the Global CVCT - Cardiovascular Clinical Trialists Forum. From our clinical development program, we shared the latest results on our lead investigational product, etripamil, for PSVT and AFib-RVR.
 
The results from our Phase 3 RAPID study for PSVT and our Phase 2 ReVeRA study for AFib-RVR demonstrate our commitment to help alleviate the provider burden in diagnosing and treating these debilitating and life-altering cardiovascular conditions and help patients actively self-manage their condition outside the healthcare setting.
 
You can learn more about our clinical development program here: https://bit.ly/47Dzq6m
 
#CVCT2023 #ClinicalTrials #ClinicalResearch

#DYK that the prevalence of atrial fibrillation (AFib) is expected to grow to approximately 10 million by 2025 and up to about 12 million by 2030, according to the American Heart Association? 
 
Recently at the American Heart Association Scientific Sessions 2023, we presented positive results from our ReVeRA Phase 2 clinical trial evaluating etripamil in AFib with rapid ventricular rate (AFib-RVR), a serious condition which presents in a subset of AFib patients, and is characterized by more severe episodic symptoms including heart palpitations, shortness of breath, dizziness, and/or weakness. 
 
One of the study investigators, Dr. James Ip from Weill Cornell Medicine, sat down with HCPLive to discuss the unmet needs for patients with AFib-RVR and the potential of etripamil nasal spray. 
 
Read more about the results from the study here: https://lnkd.in/ewrfDT8e
 
You can tune into Dr. Ip’s interview below. 
 
#AHA23 #AFib

Attending the Global CVCT - Cardiovascular Clinical Trialists Forum in Washington D.C. this weekend?
 
We look forward to sharing data on the efficacy and safety of etripamil, an investigational new drug, from our clinical trials to treat patients with paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular response (AFib-RVR). 
 
Let us know if you plan to attend in the comments. Members of our leadership team, including David Bharucha, MD, PhD and Anita Holz, MSN, CRNP, will be in attendance. We look forward to seeing you there! 
 
#CVCT2023 #ClinicalTrials #ClinicalResearch

Today, we reported our financial results for the Third Quarter 2023. Learn more about these results and progress in our clinical development program here: https://lnkd.in/e7hrGyfc

Tomorrow is the last day of #AHA23! Stop by our booth (#2911/B2659) today and tomorrow to learn more about the newly presented results from our ReVeRA Phase 2 clinical study of etripamil in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). We look forward to discussing how we are addressing the unmet need for patients living with AFib-RVR and paroxysmal supraventricular tachycardia (PSVT).  
  
You can learn more about the results of the study, simultaneously published in Circulation: Arrhythmia and Electrophysiology here: https://lnkd.in/ewrfDT8e
 
#Milestone #AFib #SVTAwareness

As part of a Featured Scientific Session at the @American Heart Association, today, we presented positive results from our ReVeRA Phase 2 clinical study of etripamil in AFib-RVR. The results were also simultaneously published in Circulation: Arrhythmia and Electrophysiology.
 
Patients with AFib-RVR continue to face a significant unmet need and our market research data suggests 30-40 percent of patients with AFib experience one or more symptomatic episodes of AFib-RVR requiring treatment. 
 
At Milestone, we are committed to helping improve the lives of people living with cardiovascular conditions. We plan to share an update on the continued development of self-administered etripamil nasal spray for AFib-RVR in the coming weeks.
 
You can learn more about the results here:

https://lnkd.in/ewrfDT8e
 
#Milestone #AFib #AHA23

Attending American Heart Association Scientific Sessions in Philadelphia from November 11-13?
 
Our team will be on the ground and looks forward to connecting and learning more about the latest advancements in #hearthealth. Come stop by our booth #2911/B2659 to learn more about the latest updates in #PSVT and #AFib and how we are working to address current unmet needs for patients. 
 
We look forward to seeing you there! 
 
#AHA23 #SVTAwareness

Join the Milestone Pharmaceuticals team the morning of Saturday, November 11 for a MedscapeLIVE Event where we will dive into paroxysmal supraventricular tachycardia (PSVT). 
 
PSVT is a life-altering disease affecting 1 in 300 patients and is characterized by spontaneous episodes of ventricular contractions exceeding rates of 100 beats per minute. During this symposium, experts will discuss hot topics on PSVT including clinical burden of disease, guideline recommendations, and current as well as emerging treatment strategies for PSVT. #AHA #HeartHealth #PSVT #SVTAwareness

We look forward to having you join us, and you can register here:

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover					0.13 -	0.07 46.36%	0.01 80.20%
cash per share	1.14 -	3.64 219.47%	7.59 108.78%	4.85 36.11%	2.73 43.74%	1.52 44.24%	0.00 99.90%
company equity multiplier	-0.83 -	-1.60 91.51%	1.07 167.32%	1.05 2.44%	1.06 1.57%	1.12 5.47%	4.49 299.56%
days of inventory outstanding
days of payables outstanding
days of sales outstanding					11.75 -	88.55 653.42%	1.17K 1,222.34%
dividend yield
ebit per revenue					-2.87 -	-11.93 315.40%	-61.10 412.21%
ebt per ebit	0.98 -	0.97 0.75%	0.96 1.55%	0.99 3.20%	0.99 0.93%	0.98 1.60%
effective tax rate	-0.00 -	-0.00 546.95%	0.00 131.63%	0.00 66.42%	0.01 1,409.47%	0.02 318.34%
enterprise value multiple	-42.69 -	-11.65 72.70%	-2.31 80.21%	-2.47 7.29%	-3.74 50.98%	-2.73 26.86%	-1.17K 42,894.91%
fixed asset turnover					16.20 -	1.87 88.48%	0.46 75.57%
free cash flow per share	-0.34 -	-0.89 160.27%	-3.27 266.97%	-1.73 47.08%	-0.79 54.06%	-1.24 56.44%	-0.00 99.91%
gross profit margin					1 -	1 0%	1 0%
interest coverage			-22.30 -	-69.85 213.27%		47.56 -	23.92 49.70%
inventory turnover
long term debt to capitalization			0.00 -	0.00 202.74%	0.00 13.38%	0.03 596.70%	0.75 2,479.57%
net income per ebt	1.00 -	1.00 0.27%	1.00 0.42%	1.00 0.07%	0.99 0.48%	0.98 1.64%
net profit margin					-2.84 -	-11.43 302.04%
operating cash flow per share	-0.34 -	-0.89 161.38%	-3.24 264.12%	-1.73 46.65%	-0.79 54.06%	-1.24 55.63%	-0.00 99.91%
operating profit margin					-2.87 -	-11.93 315.40%	-61.10 412.21%
payables turnover
pretax profit margin					-2.86 -	-11.68 308.76%
price fair value	-10.97 -	-6.58 40.01%	2.20 133.40%	1.37 37.53%	2.43 77.14%	2.53 4.12%	4.28K 168,722.70%
receivables turnover					31.06 -	4.12 86.73%	0.31 92.44%
return on assets	-0.29 -	-0.26 10.19%	-0.45 69.99%	-0.33 25.54%	-0.36 6.77%	-0.77 115.64%
return on capital employed	-0.32 -	-0.29 10.39%	-0.50 76.37%	-0.35 29.88%	-0.38 8.03%	-0.87 129.09%	-0.90 2.96%
return on equity	0.24 -	0.42 72.00%	-0.48 214.44%	-0.35 27.36%	-0.38 8.45%	-0.86 127.44%
total debt to capitalization			0.00 -	0.01 46.69%	0.01 5.68%	0.04 487.36%	0.76 1,987.37%

COM:MILESTONEPHARMA

Milestone Pharmaceuticals, Inc.

Last Close

1.85

22/11 21:00

Market Cap

98.12M

Beta: -

Volume Today

276.50K

Avg: -

Preview